Abstract：Objective: To study the clinical efficacy of mirtazapine in the treatment of patients with sleep disorders in perimenopausal period. Methods:129 cases of perimenopausal syndrome with sleep disorder were selected and divided into control group (n = 64 cases) and research group (n = 65 cases) according to random number table method. Patients in the control group were treated with oral oryzanol tablets. Patients in the study group were treated with mirtazapine tablets. The PSQI score, the HAMD-17 score, the clinical efficacy of sleep and the clinical effect of depression were compared between the two groups before treatment, 4 weeks after treatment, and 8 weeks after treatment. The EEG results and adverse drug reactions before treatment, 4 weeks after treatment and 8 weeks after treatment were compared. Results:There was no significant difference in PSQI scores between the two groups before treatment (P>0.05). After treatment, the PSQI scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment. The scores of the study group were significantly lower than the control group. In the group (P<0.05). The total effective rate of sleep efficacy in the control group was lower than in the study group (χ2=14.291, P<0.05). There was no significant difference in HAMD-17 scores between the two groups before treatment (P>0.05). After treatment, HAMD-17 scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment. The scores of the study group were Lower than the control group (P<0.05). The total effective rate of depression in the control group was lower than in the study group (χ2=12.621, P<0.05). There was no significant difference in EEG before treatment between the two groups (P>0.05). There was no significant difference between the two groups after 4 weeks of treatment (P>0.05). After 8 weeks of treatment, the study group was significantly better than the control group (P<0.05). The incidence of adverse reactions in the study group was higher than that in the control group (χ2=4.737, P<0.05). Conclusion:In the treatment of perimenopausal syndrome patients with sleep disorders, mirtazapine has a rapid onset, can improve sleep, and has a significant effect. It has little effect on EEG and has some adverse reactions, but it is necessary to continue to increase the medication time to observe further.
孙瑞坦,朴翔宇,蔡鸣,梁倩. 米氮平治疗围绝经期睡眠障碍患者的临床有效性及安全性分析[J]. 河北医学, 2018, 24(12): 2070-2072.
SUN Ruitan, PIAO Xiangyu, CAI Ming, et al. Analysis on Clinical Efficacy and Safety of Mirtazapine in treatment of Patients with Perimenopausal Sleep Disorders. HeBei Med, 2018, 24(12): 2070-2072.
2018, Vol. 24 
冀公网安备13080202000677号